Cerebral Inc., a digital mental health startup based in San Francisco, has entered a groundbreaking partnership with Field Trip Health Ltd., a Toronto-based provider of psychedelic-assisted therapies. This strategic collaboration is designed to create a seamless, end-to-end care solution that combines digital psychiatry, teletherapy, and psychedelic-assisted mental health care to address the evolving needs of today’s patients.
Through the partnership, Cerebral will refer qualifying individuals to Field Trip Health for psychedelic treatments such as ketamine-assisted therapy. In return, Field Trip will guide its patients back to Cerebral for ongoing general psychiatric services and virtual therapy. By combining resources and expertise, both companies aim to expand access to a wider spectrum of mental health services tailored to individual needs.
A Modernized Approach to Mental Health
According to Dr. David Mou, Cerebral’s Chief Medical Officer, “The recent shift in the mental health landscape has resulted in a need for modernized, digitized, and personalized solutions. We’re constantly searching for novel ways to work towards that goal, which is why we chose to partner with Field Trip, a like-minded company with an aligning ethos that brings psychedelic-assisted psychotherapy to the table for our clients.”
This partnership represents a bold step forward in psychedelic-assisted mental health care, combining the convenience and reach of virtual care with the depth and healing potential of psychedelic therapy. Cerebral, which experienced a 400% growth in its subscription base in 2021 and raised $300 million in a Series C funding round, now employs more than 2,500 licensed prescribers, therapists, and counselors across the country. The company claims to be the fastest-growing online mental health platform in the world.
Expanding Access to Psychedelic Therapy
Field Trip Health is known as North America’s largest provider of psychedelic-assisted therapy, with clinics in major U.S. cities including New York, Chicago, Atlanta, Seattle, Washington D.C., Los Angeles, San Diego, and Houston. The company also opened its first European location in Amsterdam in September, signaling global ambitions.
“Our partnership with Cerebral will lower the barriers of entry into ketamine-assisted therapy for many people who have solely been exposed to generalized psychiatry or might not have been presented with an alternative of exploring a healing journey propelled through psychedelics,” said Ronan Levy, Executive Chairman of Field Trip Health. “Together, we are changing the mental health landscape by merging teletherapy, telepsychiatry, and psychedelic-assisted mental health care into a more accessible and holistic model.”
The joint effort aims to normalize psychedelic-assisted mental health care as a valid, research-supported treatment for conditions such as depression, PTSD, and anxiety—especially for patients who haven’t found success with traditional therapies alone.
Navigating Regulatory Challenges in the U.S.
Although psychedelic-assisted mental health care is growing in popularity, regulatory challenges in the United States remain a significant obstacle. Substances like psilocybin and MDMA are still federally classified as Schedule I drugs, which makes them illegal outside of research settings. Ketamine, however, is legally prescribed in clinical settings and is currently the most accessible psychedelic used in therapy.
Despite the complex legal environment, innovation continues. Companies like Field Trip are expanding operations internationally, while others such as Delic Holdings and Origin Therapeutics are positioning themselves to capitalize on the momentum of this emerging field.
For Cerebral, the partnership represents an opportunity to offer clients a broader care spectrum while Field Trip gains access to a larger population seeking virtual care. Together, they are paving the way for a future where psychedelic-assisted mental health care becomes more mainstream and integrated into everyday psychiatric practices.
A New Standard for Personalized Mental Health
This partnership signals a significant step in the direction of patient-centered, evidence-based care. By combining the power of digital platforms with the therapeutic potential of psychedelics, Cerebral and Field Trip are meeting patients where they are—both geographically and emotionally.
For many individuals, psychedelic-assisted mental health care offers a chance to heal in ways traditional methods have not. With this new partnership, more people will have the opportunity to access alternative therapies through a trusted clinical model that includes ongoing psychiatric oversight, professional therapy, and personalized treatment plans.
As the mental health field evolves, so too must the tools and approaches it relies on. Integrating telehealth with psychedelic-assisted mental health care may prove to be one of the most promising strategies for addressing the growing mental health crisis. Patients deserve innovative, science-backed, and accessible solutions—and this partnership is working to deliver exactly that.
Looking Ahead
While financial details of the agreement were not released, the mission is clear: to revolutionize how mental health care is delivered by combining innovation, accessibility, and clinical depth. The Cerebral–Field Trip partnership marks a key milestone in the effort to destigmatize and expand access to psychedelic-assisted mental health care.
As more research supports the effectiveness of psychedelic therapies and digital platforms continue to expand, partnerships like this one may become the new gold standard. For now, it’s a bold first move toward redefining how we care for mental health—digitally, holistically, and with greater possibility than ever before.
